Amgen Inc. (AMGN) Borrowing debt
- Total debt · latest quarter (USD): Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-30..
- Net cash · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-30..
- Debt / assets · latest quarter: Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-30..
Borrowing debt
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total debt · latest quarter (USD) | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Net cash · latest quarter | (m) | Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Debt / assets · latest quarter | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Borrowing debt due within one year | 5.45B USD | Long-term Debt, Current Maturities |
| Borrowing debt due after one year | 51.86B USD | Long-term Debt, Excluding Current Maturities |
| Commercial paper | (m) | Commercial Paper |
| Cash and current securities | (m) | Cash and Cash Equivalents, at Carrying Value · Debt Securities, Available-for-sale, Current · Available-for-sale Securities, Current |
| Borrowing debt | (m) | Long-term Debt, Current Maturities · Long-term Debt, Excluding Current Maturities · Commercial Paper |
| Total assets | 95.64B USD | Assets |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total debt | Net cash / debt | Borrowing debt due within one year (USD) | Borrowing debt due after one year (USD) | Commercial paper (USD) | Cash and current securities (USD) | Total assets (USD) | Debt / assets |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $5.45B | $51.86B | (m) | (m) | $95.64B | (m) |
| 2026-03-31 | (m) | (m) | $5.44B | $51.89B | (m) | (m) | $92.50B | (m) |
| 2025-12-31 | $54.60B | (m) | $4.60B | $50.01B | $0.00 | (m) | $90.59B | 60.28% |
| 2025-09-30 | (m) | (m) | $2.15B | $52.43B | (m) | (m) | $90.14B | (m) |
| 2025-06-30 | (m) | (m) | $2.44B | $53.76B | (m) | (m) | $87.90B | (m) |
| 2025-03-31 | (m) | (m) | $3.37B | $54.01B | (m) | (m) | $89.37B | (m) |
| 2024-12-31 | $60.10B | (m) | $3.55B | $56.55B | $0.00 | (m) | $91.84B | 65.44% |
| 2024-09-30 | (m) | (m) | $3.54B | $56.85B | (m) | (m) | $90.88B | (m) |
| 2024-06-30 | (m) | (m) | $5.53B | $57.12B | (m) | (m) | $90.91B | (m) |
| 2024-03-31 | (m) | (m) | $3.96B | $60.06B | (m) | (m) | $92.98B | (m) |
| 2023-12-31 | $64.61B | $53.67B | $1.44B | $63.17B | $0.00 | $10.94B | $97.15B | 66.51% |
| 2023-09-30 | (m) | (m) | $1.43B | $59.04B | (m) | $34.74B | $90.53B | (m) |
| 2023-06-30 | (m) | (m) | $2.17B | $59.38B | (m) | $34.25B | $90.27B | (m) |
| 2023-03-31 | (m) | (m) | $834.00M | $60.76B | (m) | $31.56B | $88.72B | (m) |
| 2022-12-31 | $38.95B | $29.64B | $1.59B | $37.35B | $0.00 | $9.30B | $65.12B | 59.80% |
| 2022-09-30 | (m) | (m) | $1.54B | $37.16B | (m) | $11.48B | $63.70B | (m) |
| 2022-06-30 | (m) | (m) | $817.00M | $35.70B | (m) | $7.18B | $59.29B | (m) |
| 2022-03-31 | (m) | (m) | $844.00M | $36.01B | (m) | $6.54B | $59.20B | (m) |
| 2021-12-31 | (m) | (m) | $87.00M | $33.22B | (m) | $8.04B | $61.16B | (m) |
| 2021-09-30 | (m) | (m) | $4.29B | $33.29B | (m) | $12.92B | $64.99B | (m) |
| 2021-06-30 | (m) | (m) | $4.32B | $28.46B | (m) | $8.08B | $59.77B | (m) |
| 2021-03-31 | (m) | (m) | $1.56B | $31.13B | (m) | $10.57B | $62.54B | (m) |
| 2020-12-31 | (m) | (m) | $91.00M | $32.90B | (m) | $10.65B | $62.95B | (m) |
| 2020-09-30 | (m) | (m) | $91.00M | $34.20B | (m) | $12.36B | $64.64B | (m) |
| 2020-06-30 | (m) | (m) | $91.00M | $34.13B | (m) | $11.42B | $65.01B | (m) |
| 2020-03-31 | (m) | (m) | $1.84B | $30.01B | (m) | $8.01B | $61.67B | (m) |
| 2019-12-31 | (m) | (m) | $2.95B | $26.95B | (m) | $8.91B | $59.71B | (m) |
| 2019-09-30 | (m) | (m) | $2.05B | $27.74B | (m) | $20.85B | $59.53B | (m) |
| 2019-06-30 | (m) | (m) | $2.82B | $27.80B | (m) | $21.76B | $59.37B | (m) |
| 2019-03-31 | (m) | (m) | $3.71B | $29.32B | (m) | $26.30B | $64.00B | (m) |
| 2018-12-31 | (m) | (m) | $4.42B | $29.51B | (m) | $29.30B | $66.42B | (m) |
| 2018-09-30 | (m) | (m) | $5.08B | $29.35B | (m) | $29.92B | $67.33B | (m) |
| 2018-06-30 | (m) | (m) | $4.29B | $30.21B | (m) | $29.39B | $67.68B | (m) |
| 2018-03-31 | (m) | (m) | $2.18B | $33.36B | (m) | $32.17B | $71.16B | (m) |
| 2017-12-31 | (m) | (m) | $1.15B | $34.19B | (m) | $41.68B | $79.95B | (m) |
| 2017-09-30 | $37.28B | $4.08B | $2.00B | $33.78B | $1.50B | $41.35B | $80.33B | 46.40% |
| 2017-06-30 | $36.02B | $3.21B | $1.46B | $33.60B | $960.00M | $39.23B | $79.59B | 45.26% |
| 2017-03-31 | (m) | (m) | $3.80B | $30.29B | (m) | $38.40B | $77.86B | (m) |
| 2016-12-31 | (m) | (m) | $4.40B | $30.19B | (m) | $38.09B | $77.63B | (m) |
| 2016-09-30 | (m) | (m) | $4.80B | $30.53B | (m) | $37.98B | $78.15B | (m) |
| 2016-06-30 | (m) | (m) | $5.29B | $27.93B | (m) | $35.03B | $75.47B | (m) |
| 2016-03-31 | (m) | (m) | $2.25B | $32.06B | (m) | $34.74B | $75.12B | (m) |
| 2015-12-31 | (m) | (m) | $2.25B | $29.31B | (m) | $31.38B | $71.58B | (m) |
| 2015-09-30 | (m) | (m) | $1.25B | $30.51B | (m) | $31.12B | $71.87B | (m) |
| 2015-06-30 | (m) | (m) | $1.25B | $30.70B | (m) | $29.99B | $71.21B | (m) |
| 2015-03-31 | (m) | (m) | $500.00M | $29.84B | (m) | $27.12B | $68.95B | (m) |
| 2014-12-31 | (m) | (m) | $500.00M | $30.21B | (m) | $27.03B | $69.01B | (m) |
| 2014-09-30 | (m) | (m) | $2.50B | $30.48B | (m) | $28.07B | $70.78B | (m) |
| 2014-06-30 | (m) | (m) | $2.50B | $30.83B | (m) | $26.19B | $69.53B | (m) |
| 2013-12-31 | (m) | (m) | $2.50B | $29.62B | (m) | $19.40B | $66.13B | (m) |
| 2011-09-30 | (m) | (m) | (m) | (m) | $300.00M | $17.68B | $45.77B | (m) |
| 2011-06-30 | (m) | (m) | (m) | $13.85B | (m) | $19.17B | $46.94B | (m) |
| 2011-03-31 | (m) | (m) | (m) | $10.82B | (m) | $15.36B | $42.71B | (m) |
| 2010-12-31 | (m) | (m) | (m) | $10.87B | (m) | $17.42B | $43.49B | (m) |
| 2010-09-30 | (m) | (m) | (m) | $10.84B | (m) | $17.05B | $43.53B | (m) |
| 2010-06-30 | (m) | (m) | (m) | $9.32B | (m) | $14.52B | $40.80B | (m) |
| 2009-12-31 | (m) | (m) | (m) | $10.60B | (m) | $13.44B | $39.63B | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GILEAD SCIENCES, INC. (GILD) | United States | $185.522B | -48.37 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |